Coya Therapeutics (NASDAQ:COYA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10), FiscalAI reports. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.11 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.
Coya Therapeutics Stock Performance
Shares of Coya Therapeutics stock traded down $0.01 during trading hours on Tuesday, reaching $3.31. 34,144 shares of the company were exchanged, compared to its average volume of 178,805. Coya Therapeutics has a 1 year low of $2.72 and a 1 year high of $6.62. The firm has a market cap of $77.77 million, a PE ratio of -3.10 and a beta of 0.70. The stock’s fifty day moving average is $4.40 and its 200 day moving average is $4.61.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating and set a $16.00 price target on shares of Coya Therapeutics in a report on Tuesday, September 15th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, Roth Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Coya Therapeutics in a report on Monday, August 24th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.
Read Our Latest Research Report on COYA
Coya Therapeutics Company Profile
Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.
The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.
Further Reading
- Five stocks we like better than Coya Therapeutics
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
